Fig. 5

TTC17/RAP1/CDC42 pathway activation correlated with the clinical metastasis and aggressive characteristics of breast cancer. a, b Representative images and quantitative analysis of IHC staining of TTC17 (a) and the RAP1 signaling pathway effector CDC42 (b) in the primary tumor and metastatic lymph node tissues of breast cancer patients. Scale bars, a 50 μm, b 50 μm. c Representative IHC images and quantitative analysis of ATP5A expression in patients with breast cancer. Scale bar, 100 μm. d, e Correlation between the expression of TTC17 and tumor histopathologic grade (d) together with the Ki-67 index (e) in our breast cancer cohort. f Univariate and multivariate logistic regression analysis of the linkage between TTC17 expression and clinicopathological features in breast cancer patients using data archived in TCGA. Bold text represents statistically significant difference. IHC, immunohistochemistry; non-mPT, non-metastatic primary tumor; mPT, metastatic primary tumor; mLN, metastatic lymph node; TCGA, The Cancer Genome Atlas CI, confidence interval; ILC, infiltrating lobular carcinoma; IDC, infiltrating ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; lum A, luminal A; lum B, luminal B